Pharmacy-administered IV to oral therapeutic interchange program: Development, implementation, and cost-assessment

Hospital Pharmacy

Volumn 38, Issue 5, 2003, Pages

  Fox, Erin R ^a   Beckwith, M Christina ^a   Tyler, Linda S ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Cost reduction; Therapeutic interchange

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; FAMOTIDINE; FLUCONAZOLE; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; PANTOPRAZOLE; RIFAMPICIN;

ARTICLE; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG COST; HEALTH PROGRAM; HUMAN; NURSING; PHARMACY;

EID: 0038629463     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870303800512     Document Type: Article

References (30)

1. Nightingale CH, Quintiliani R. Cost of oral antibiotic therapy. Pharmacotherapy. 1997;17:302-7.
2. Hunter KA, Dormaier GK. Pharmacist-managed intravenous to oral stepdown program. Clin Ther. 1995;17:534-40.
3. Ramirez JA. Antibiotic streamlining: development and justification of an antibiotic streamlining program. Pharm Pract Manag Q. 1996;16:19-34.
4. Ehrenkranz NJ, Nerenberg DE, Shultz JM, et al. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol. 1992;13:21-32.
5. Drew RH. Programs promoting timely sequential antimicrobial therapy: An American perspective. J Infect. 1998;37(suppl 1):3-9.
6. Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998;92:1032-9.
7. Cunha BA. Intravenous-to-oral antibiotic switch therapy. A cost-effective approach. Postgrad Med. 1997; 101:111-2,115-8,122-3.
8. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy. 1997; 17:271-6.
9. Frighetto L, Nickoloff D, Martinusen SM, et al. Intravenous-to-oral stepdown program: Four years of experience in a large teaching hospital. Ann Pharmacother. 1992;26:1447-51.
10. 2-receptor antagonist therapy. DICP. 1991;25:804.
11. Nathwani D. Sequential switch therapy for lower respiratory tract infections: A European perspective. Chest. 1998;113:211S-8S.
12. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with communityacquired pneumonia. Arch Intern Med. 1999;159:2449-54.
13. Wong-Beringer A, Nguyen KH, Razeghi J. Implementing a program for switching from IV to oral antimicrobial therapy. Am J Health Syst Pharm. 2001; 58:1146-9.
14. Goldwater SH, Neal-Janifer A, Milkovich G, et al. Smoothing the path for IV-to-oral conversion. Am J Health Syst Pharm. 1997;54:200,205.
15. Wright DH, Pletz SL, Rotschafer JC, et al. In vitro concentration of fluoroquinolones following admixture in an enteral feeding formula (Ensure) and divalent solution [poster]. American Society of Health-System Pharmacists 32nd Annual Midyear Clinical Meeting, Atlanta, GA; December 8, 1997.
16. Wright DH, Pietz SL, Konstantinides FN, et al. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enteral Nutr. 2000; 24:42-8.
17. Mueller BA, Brierton DG, Abel SR, et al. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1994;38:2101-5.
18. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998; 24:1047-51.
19. Ahkee S, Smith S, Newman D, et al. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: A 6-month prospective study. Pharmacotherapy. 1997;17:569-75.
20. Ramirez JA. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia. Ann Pharmacother. 1998; 32:S22-6.
21. Chan R, Hemeryck L, O'Regan M, et al. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ. 1995;310:1360-2.
22. Davey P, Nathwani D. Sequential antibiotic therapy: The right patient, the right time and the right outcome. J Infect. 1998;37(suppl 1):37-44.
23. Plouffe JF, Niederman MS, Greenberg RN, et al. Safety of IV/oral azithromycin versus cefuroxime + erythromycin in patients with communityacquired pneumonia (CAP). Paper presented at the American Society for Microbiology. Atlanta, GA; May 1998.
24. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The IntraAbdominal Infection Study Group. Ann Surg. 1996;223:303-15.
25. Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenemcilastatin in the treatment of intraabdominal infections. Pharmacoeconomics. 1999;16:551-61.
26. Rimmer DM. Oral cephalosporins for use in a parenteral-to-oral switch programme. Infection. 1995;23(suppl 2):S87-S90.
27. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with communityacquired pneumonia. Arch Intern Med. 1995;155:1273-6.
28. Zamin MT, Pitre MM, Conly JM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother. 1997; 31:564-70.
29. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg. 2000;232:254-62.
30. Hutchison TA, Shahan DR, Anderson ML, Eds. Drugdex System. Englewood, CO: Micromedex, Inc.; Edition expires March 2003.